Onkologie最新文献_第6页

[Foreword]. (前言)。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-07 DOI: 10.1159/000350919

Axel Hauschild, Oliver Kölbl, Andreas Mackensen, Dirk Schadendorf

引用次数: 0

5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection. 5-氟尿嘧啶、丝裂霉素和k多糖对局部晚期胃癌根治性切除患者的辅助免疫化疗效果比较

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-06-22 DOI: 10.1159/000349957

Mi-Sun Ahn, Seok-Yun Kang, Hyun-Woo Lee, Seong-Hyun Jeong, Joon-Seong Park, Kwang-Jae Lee, Yong-Kwan Cho, Sang-Uk Han, Soon-Young Lee, Ho-Yeong Lim, Jin-Hyuk Choi

{"title":"5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.","authors":"Mi-Sun Ahn, Seok-Yun Kang, Hyun-Woo Lee, Seong-Hyun Jeong, Joon-Seong Park, Kwang-Jae Lee, Yong-Kwan Cho, Sang-Uk Han, Soon-Young Lee, Ho-Yeong Lim, Jin-Hyuk Choi","doi":"10.1159/000349957","DOIUrl":"https://doi.org/10.1159/000349957","url":null,"abstract":"Background: Despite the small but significant survival benefit of adjuvant chemotherapy in locally advanced gastric cancer (LAGC), the optimal regimen remains to be determined. We conducted a randomized trial comparing oral (PO) chemoimmunotherapy (CITX) with intravenous (IV) CITX in LAGC patients (stages IB-IIIB) with curative resection (≥ D2 dissection). Methods: The patients were randomized to the IV (5-fluorouracil 500 mg/m2 weekly for 24 weeks, mitomycin-C 8 mg/m2 every 6 weeks × 4) or the PO (uracil-ftorafur (UFT) 400-600 mg/day for 12 months) group. Patients in both groups received PO polysaccharide-K (3 g/day for 4 months). The planned number of patients was 368 for proving the non-inferiority of PO CITX compared to IV CITX for overall survival. Results: The trial was closed prematurely after enrolling 82 patients (44 in the IV group, 38 in the PO group). With a median follow-up of 82 months, there were no significant differences in the 5-year disease-free survival (73% vs. 55%, p = 0.358) and overall survival (77% vs. 66%, p = 0.159) between the 2 groups. The IV group demonstrated a higher incidence of grade 2 or 3 neutropenia, thrombocytopenia, and vomiting. Conclusions: PO CITX with UFT appeared to be at least non-inferior to 5-fluorouracil and mitomycin-C CITX, with lower toxicity in the adjuvant treatment for LAGC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 7-8","pages":"421-6"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000349957","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31638494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Expression of Rac1, HIF-1α, and VEGF in gastric carcinoma: correlation with angiogenesis and prognosis. 胃癌组织中Rac1、HIF-1α和VEGF的表达与血管生成及预后的关系

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-02-25 DOI: 10.1159/000348525

Hongjie Zhan, Han Liang, Xiangyu Liu, Jingyu Deng, Baogui Wang, Xishan Hao

{"title":"Expression of Rac1, HIF-1α, and VEGF in gastric carcinoma: correlation with angiogenesis and prognosis.","authors":"Hongjie Zhan, Han Liang, Xiangyu Liu, Jingyu Deng, Baogui Wang, Xishan Hao","doi":"10.1159/000348525","DOIUrl":"https://doi.org/10.1159/000348525","url":null,"abstract":"Background: The aim of this study was to investigate the relationship between the expression of hypoxia-inducible factor-1α (HIF-1α), Ras-related C3 botulinum toxin substrate 1 (Rac1), and vascular endothelial growth factor (VEGF), as well as their correlation with angiogenesis and prognosis in gastric carcinoma.Material and methods: The expression of Rac1, HIF-1α, VEGF, and CD34 (described in terms of microvessel density, MVD) was determined by immunohistochemical staining of tissues from 60 radically resected gastric cancer specimens.Results: The proportion of specimens expressing Rac1, HIF-1α, and VEGF was 37/60 (61.7%), 35/60 (58.3%), and 40/60 (66.7%), respectively. The levels of Rac1, HIF-1α, and VEGF expression were significantly correlated with Lauren's classification, lymph node metastasis, and pathologic staging (p < 0.05). There were positive correlations between MVD and the expression of Rac1, HIF-1α, and VEGF. The mean survival time and 5-year survival rate in cases with positive Rac1, HIF-1α, and VEGF expression and MVD ≥ 26.3 were significantly shorter than those with negative Rac1, HIF-1α, and VEGF expression and MVD < 26.3.Conclusion: Rac1, HIF-1α, and VEGF play an important role in tumor invasion and metastasis, especially in tumor angiogenesis. Thus, testing the expression of Rac1, HIF-1α, and VEGF may be a useful index for treatment and prognosis.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 3","pages":"102-7"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000348525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31303971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients. 颅磁共振成像在her2阳性乳腺癌患者分期中的意义。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-03-18 DOI: 10.1159/000349950

Muhammet A Kaplan, Ali Inal, Mehmet Kucukoner, Zuhat Urakci, Faysal Ekici, Ugur Firat, Seyit B Zincircioglu, Abdurrahman Isikdogan

{"title":"Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients.","authors":"Muhammet A Kaplan, Ali Inal, Mehmet Kucukoner, Zuhat Urakci, Faysal Ekici, Ugur Firat, Seyit B Zincircioglu, Abdurrahman Isikdogan","doi":"10.1159/000349950","DOIUrl":"https://doi.org/10.1159/000349950","url":null,"abstract":"Aim: The aim of the current study was to evaluate whether early detection of brain metastases (BMs) could improve survival outcomes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients.Material and methods: HER2-positive breast cancer patients without BMs who had no neurological symptoms within 12 months from diagnosis or relapse time of the disease were included in the study. The patients were distributed into 2 groups: Group 1 comprised patients without metastases; group 2 comprised patients with metastases. The symptomatic historic control group with BMs was defined retrospectively for survival comparisons.Results: 55 (57.3%) and 41 (42.7%) patients were in groups 1 and 2, respectively. 11 of the 96 patients (11.5%) had occult BMs, and 9 of them were in group 2 whereas only 2 patients were in group 1 (22% vs. 3.6%, respectively; p = 0.008). While the median survival times from the first metastasis (28.7 vs. 22.5 months, respectively; p = 0.561) and BM (6.8 vs. 6.1 months, respectively; p = 0.511) were similar, cerebral death was numerically different (16.7% vs. 46.3%; p = 0.221) between asymptomatic (n = 9) and symptomatic patients (n = 53).Conclusions: BMs were detected very rarely in asymptomatic, non-metastatic HER2-positive breast cancer patients compared with asymptomatic, metastatic patients. Furthermore, although early detection of BMs decreases the cerebral death rate, it does not prolong the survival rate in metastatic patients.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 4","pages":"176-81"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000349950","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40242508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Fatal cisplatin overdose in the treatment of mediastinal lymphoma with the ESHAP regimen - analysis of the causes of the adverse drug event. ESHAP方案治疗纵隔淋巴瘤致死性顺铂过量-药物不良事件原因分析

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-01-28 DOI: 10.1159/000346677

Tomasz Jurek, Marta Rorat, Piotr Dys, Barbara Swiatek

{"title":"Fatal cisplatin overdose in the treatment of mediastinal lymphoma with the ESHAP regimen - analysis of the causes of the adverse drug event.","authors":"Tomasz Jurek, Marta Rorat, Piotr Dys, Barbara Swiatek","doi":"10.1159/000346677","DOIUrl":"https://doi.org/10.1159/000346677","url":null,"abstract":"Background: Cisplatin is a chemotherapeutic agent that may cause acute (or chronic) organ toxicity. As there is no antidote, prevention of adverse drug events is essential for patients' safety.Case report: The authors present the case of a 33-year-old woman treated for lymphoma with the ESHAP regimen, who died of an overdose of cisplatin. The drug was administered at a rate 4 times greater than the recommended maximum dose. The first symptom of overdose - partial hearing loss - appeared after administration of the last dose of the drug on day 4 of the chemotherapy course. The initiation of intensive treatment with plasmapheresis and dialyses was ineffective. The patient died 18 days after receiving the last dose of cisplatin. The medication schedule had been prepared by an inexperienced physician. The information on cisplatin dosage had been sourced from a vague instruction in a clinical oncology manual: '100 mg/m(2) continuous i.v. infusion d.1-4'. The instruction was misinterpreted. The patient was given 100 mg/m(2) on each of the 4 days of the treatment.Conclusion: Special care must be taken when preparing a medication schedule; the treatment must be checked by an experienced physician and verified by the nursing staff. The patient should be monitored for symptoms of cisplatin intoxication.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 1-2","pages":"49-52"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000346677","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31346846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates. 模型计算量化血小板浓缩物中病原体灭活的临床和经济效果。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-01-22 DOI: 10.1159/000346309

Karin Berger, Matthaeus Bauer, Dorothee Schopohl, Reinhard Henschler, Helmut Ostermann

{"title":"Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates.","authors":"Karin Berger, Matthaeus Bauer, Dorothee Schopohl, Reinhard Henschler, Helmut Ostermann","doi":"10.1159/000346309","DOIUrl":"https://doi.org/10.1159/000346309","url":null,"abstract":"Background: Future shortages in platelet supply are expected in Germany due to demographic changes. A rising cancer incidence will lead to an increasing demand for platelet concentrates (PCs) while the number of potential donors will decrease. Pathogen inactivation (PI) aims to inactivate various infectious agents including emerging pathogens to extend the shelf-life of PCs and reduce the frequency of acute transfusion reactions (ATRs). In this context, the clinical and economic impact of PI on platelet transfusion was evaluated.Material and methods: Model calculations were conducted for 2 scenarios considering different production settings. Frequencies of ATRs were based on literature analyses, platelet and ATR costs on cost analyses.Results: The estimated average costs for ATRs of grade 1 and 2, irrespective of origin, and grade 3 (allergic) were € 104, € 238, and € 1,200, respectively. Approximately 400 PC-related ATRs per 10(5) transfusions can be avoided, with estimated savings amounting to € 77,000. The total cost increase was calculated to approximately € 30-50 per PI-treated PC.Conclusion: PI potentially saves plasma, prolongs shelf-life, decreases donor deferral, and reduces ATRs. Model calculations considering clinical and safety benefits of PI show a rational cost increase. The impact of PI should be further evaluated from a societal perspective regarding future blood supply and infectious disease globalization.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 1-2","pages":"53-9"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000346309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31346847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

A case of positive mixed epithelial/mesenchymal metaplastic breast carcinoma (carcinosarcoma). Towards novel therapeutic targets: case report. 阳性混合上皮/间质化生性乳腺癌(癌肉瘤)1例。迈向新的治疗靶点:个案报告。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-08-19 DOI: 10.1159/000354638

Ekaterini C Tampaki, Athanasios Tampakis, George Agrogiannis, Nikolaos Kavantzas, Konstantinos Kontzoglou, Gregory Kouraklis

{"title":"A case of positive mixed epithelial/mesenchymal metaplastic breast carcinoma (carcinosarcoma). Towards novel therapeutic targets: case report.","authors":"Ekaterini C Tampaki, Athanasios Tampakis, George Agrogiannis, Nikolaos Kavantzas, Konstantinos Kontzoglou, Gregory Kouraklis","doi":"10.1159/000354638","DOIUrl":"https://doi.org/10.1159/000354638","url":null,"abstract":"Background: Metaplastic breast cancer (MeBC) is a rare malignancy, representing less than 1% of all breast cancers. We present a case of triple-negative MeBC with a biphasic growth pattern, including malignant mesenchymal and epithelial components.Case report: A 45-year-old female patient presented to our hospital with a 1-month history of a lump in her right breast. Upon clinical examination, a mass measuring 24 mm in diameter was revealed at 10-11 o'clock in the outer upper quadrant of the right breast. The patient was submitted for ultrasound scanning, ultrasound-guided core needle biopsy, and excisional biopsy which revealed a mixed epithelial/mesenchymal tumor, 8 cm in diameter. A complete immunohistochemical profile was presented. A right modified radical mastectomy with axillary lymph node dissection was performed and was tolerated well by the patient. The histological diagnosis of the lesion was MeBC with the epithelial component consistent with a grade 3 ductal adenocarcinoma. The 14 dissected axillary nodes were not involved. The patient was later submitted for adjuvant chemotherapy and radiotherapy. To date, 24 months postoperatively, the patient remains without any signs or symptoms of residual disease or recurrence.Conclusion: The aggressive behavior and chemoresistance of MeBC warrants early diagnosis and treatment to achieve optimal outcome.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 9","pages":"506-9"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000354638","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31746553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany. 早期乳腺癌在德国城市和农村乳腺癌治疗单位的结果。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-08-19 DOI: 10.1159/000354624

Florian Heitz, Alexandra Bender, Jana Barinoff, Fatemeh Lorenz-Salehi, Annette Fisseler-Eckhoff, Alexander Traut, Rita Hils, Philipp Harter, Uwe Kullmer, Andreas du Bois

{"title":"Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany.","authors":"Florian Heitz, Alexandra Bender, Jana Barinoff, Fatemeh Lorenz-Salehi, Annette Fisseler-Eckhoff, Alexander Traut, Rita Hils, Philipp Harter, Uwe Kullmer, Andreas du Bois","doi":"10.1159/000354624","DOIUrl":"https://doi.org/10.1159/000354624","url":null,"abstract":"Background: Conflicting evidence has been published concerning survival disadvantages in the outcome of breast cancer patients in relationship to their residency in urban or rural communities.Methods: The primary aim of this study was to evaluate differences in patients and treatment characteristics between an urban and a rural breast cancer unit. Therefore, all early breast cancer patients treated consecutively between 1999 and 2007 in a rural and an urban breast cancer unit were included. Patient and tumor characteristics, treatment strategies, and guideline adherence were included to evaluate the prognoses of both populations.Results: Overall, data from 2,566 patients were included in this analysis. The 610 patients treated in the rural unit showed significantly more negative prognostic criteria than the 1,956 patients treated in the urban center. No differences were observed with respect to surgical and systemic treatment after adjustment for prognostic parameters. Adherence to national guidelines did not differ significantly between both settings and ranged between 78.0 and 95.6%. Furthermore, no differences regarding recurrence-free and overall survival were observed.Conclusions: The stage-adjusted pattern of care was similar in 2 German breast care units in a rural region and an urban area. Nevertheless, an earlier diagnosis of breast cancer should be enforced in rural areas to avoid extended treatment burden.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 9","pages":"477-82"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000354624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31746628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Exploration of the role of radiotherapy in the management of early glottic cancer with complete carotid artery occlusion. 探讨放疗在早期声门癌合并颈动脉完全闭塞的治疗中的作用。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-07-08 DOI: 10.1159/000353750

Waleed F Mourad, Kenneth S Hu, Rania A Shourbaji, James Dolan, Dukagjin M Blakaj, Daniel Shasha, Louis B Harrison

{"title":"Exploration of the role of radiotherapy in the management of early glottic cancer with complete carotid artery occlusion.","authors":"Waleed F Mourad, Kenneth S Hu, Rania A Shourbaji, James Dolan, Dukagjin M Blakaj, Daniel Shasha, Louis B Harrison","doi":"10.1159/000353750","DOIUrl":"https://doi.org/10.1159/000353750","url":null,"abstract":"Background: The aim of this study was to compare intensity-modulated radiation therapy (IMRT) vs. 2D and 3D radiotherapy (RT) in the treatment of T1 glottic squamous cell carcinoma in an effort to highlight the advantages of IMRT in this particular clinical situation.Case report: We present the case of an 82-year-old female patient with T1 left true vocal cord squamous cell carcinoma and complete occlusion of the left carotid artery resulting in multiple strokes. The patient underwent definitive RT with 63 Gy (28 × 2.25 Gy). 3 plans were generated: 2D RT, 3D RT, and IMRT. The right carotid artery (Rt.CA) mean dose was 865, 2,065, and 4,268 cGy for IMRT, 3D RT, and 2D RT, respectively. The inferior pharyngeal constrictor (IPC) mean dose was 5,341, 6,456, and 6,451 cGy for IMRT, 3D RT, and 2D RT, respectively. IMRT provided the best homogeneity but at a higher cost and with prolonged treatment time.Conclusion: IMRT provided the finest planning target volume coverage with minimal Rt.CA and IPC doses. IMRT is recommended in certain clinical scenarios which are not manageable with other techniques.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 7-8","pages":"433-5"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000353750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31638496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report. 血清S100B水平与CTLA-4阻断治疗的转移性黑色素瘤患者的临床获益相关:一个病例报告。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-09-17 DOI: 10.1159/000355159

Carmen Loquai, Tina Müller-Brenne, Simin Schadmand-Fischer, Stephan Grabbe

{"title":"Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.","authors":"Carmen Loquai, Tina Müller-Brenne, Simin Schadmand-Fischer, Stephan Grabbe","doi":"10.1159/000355159","DOIUrl":"https://doi.org/10.1159/000355159","url":null,"abstract":"Background: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells. In patients with metastatic melanoma, anti-CTLA-4 antibody therapy with ipilimumab achieves durable cancer regression in approximately 10-15% of patients. In the face of complex and sometimes delayed tumor response patterns, prognostic and predictive biomarkers are needed to monitor therapy outcomes and to identify early potential long-term survivors who might also benefit from therapy re-induction.Case report: The clinical case of a 49-year-old male patient with metastatic melanoma and unfavorable prognostic factors is presented. The time course of the serum biomarker S100B during initial anti-CTLA-4 therapy correlated very well with the clinical situation and, in the present case, proved its potential value as an early biomarker of a subsequently observed radiological response in this stage IV melanoma patient. The observed clinical response lasted for more than 24 months.Conclusions: Further efforts are required to better understand the patterns of response and the immunological tumor response in patients undergoing CTLA-4 blockade. A validation of S100B as a marker to identify early long-term responders among patients treated with ipilimumab is warranted.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"578-81"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31792071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5